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Commentary
Dengue Virus: Protection by T Cells, Disease Exacerbation by Antibodies?
Christian Münz
Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Switzerland
The insect transmitted arboviruses among the ﬂaviviruses pose a
signiﬁcant health risk to humans as observed during the recent Zika
virus outbreak in South America (Lessler et al., 2016). One of the most
prominent members of this group of pathogens is Dengue virus
(DENV), which exists in four serotypes, DENV1–4 (Bhatt et al., 2013;
Messina et al., 2014).While infection with one serotype confers protec-
tion against reinfectionwith the same serotype and is usually associated
with onlymild symptoms, exposure to a different serotype can cause se-
vere disease, resulting in vascular leakage, uncontrolled cytokine levels
and hemorrhagic fever. Especially delayed exposure to a second sero-
type from several months to three years after primary DENV infection
increases the risk for severe disease (Montoya et al., 2013). This
suggests that waning DENV-speciﬁc immunity which diminishes pro-
tective cross-reactive immune responses against other serotypes can
even exacerbate disease. Both the humoral and the cell-mediated arm
of the immune system have been suspected to be responsible for this
exacerbation. Cross-reactive, but not protective antibody responses
might exacerbate infection by antibody-dependent enhancement
(ADE) (Zellweger et al., 2010). In addition, original antigenic sin (OAS)
has been proposed to focus T cell responses during infection with one
serotype towards speciﬁcities that upon reinfection with another sero-
type are not protective, but get re-stimulated to produce immune path-
ological inﬂammation (Rothman, 2011). Distinguishing between these
two possibilities is of utmost importance to design broadly protective
vaccine candidates (Guy et al., 2016).
Supporting the idea that T cell responses may be cross-reactive, the
human MHC class I HLA-B*0702 molecule was found to be associated
with resistance to severe DENV infection upon exposure to different se-
rotypes (Weiskopf et al., 2013). Building on these ﬁndings the study by
Elong Ngono and colleagues in this issue of EBioMedicine explores CD8+
T cell responses against DENV non-structural proteins (NS) 3, 4B and 5
in HLA-B*0702 transgenic type I IFN receptor deﬁcient mice (Elong
Ngono et al., 2016). Even though the authors found diminished reactiv-
ity of some DENV2 epitope-induced CD8+ T cell responses against the
respective sequences of the other serotypes, the respective CD8+ T
cells were able to produce multiple cytokines upon re-stimulation
with peptides from all serotypes. More importantly, challenge with
DENV2 or DENV3 infection resulted in similar protection after vaccina-
tion with DENV2 or DENV1/3/4 derived peptides. These ﬁndings
suggest that CD8+ T cell responses against DENV NS proteins canmedi-
ate protective cross-reactive immunity. However, it needs to be deter-
mined in the future if this is a particular feature of the protective HLA-
B*0702 allele that was used in this study or can be generalized to
most HLA haplotypes.
If such protective cross-reactivity can, however, be demonstrated
across most HLA haplotypes, then immunodominant CD8+ T cell
antigens should be preferentially included into DENV-speciﬁc vaccina-
tion approaches. Following this line of thought, live-attenuated viral
vectors, which stimulate CD8+ T cell responses most efﬁciently, might
constitute a promising vaccine formulation (Guy et al., 2016). Along
these lines, the live-attenuated vaccine of yellow fever virus (YV17D),
another arbovirus of the ﬂavivirus family, seems to be among the
most successful vaccinations in humans (Gotuzzo et al., 2013). Howev-
er, the NS antigens of DENV, which seem to provide dominant CD8+ T
cell stimulation, should be included in such a protective T cell directed
vaccination with live-attenuated viruses.
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